10058-F4 is a c-Myc inhibitor that prevents c-Myc/Max dimerization. c-Myc is a proto-oncogene that plays an important role in cell proliferation, differentiation, and apoptosis. 10058-F4 has been shown to arrest cell growth at G0/G1 phase. Experiments show that extended exposure to 10058-F4 causes apoptosis via upregulation of Bax, expression of cytoplasmic Cytochrome C, down-regulation of Bcl-2, and cleavage of caspase-3,-7, and -9. This compound has been found to also upregulate cyclin-dependent kinase inhibitors, p21 and p27.
1. Huang, M.J., et al. 2006. Exp. Hematol. 34: 1480-1489. PMID: 17046567
2. Lin, C.P., et al. 2007. Anticancer Drugs. 18: 161-170. PMID: 17159602
3. Guo, J., et al. 2009. Cancer Chemother. Pharmacol. 63: 615-625. PMID: 18509642
See how others have used 10058-F4. Click on the entry to view the PubMed entry .
PMID: # 28402964 Ren, X. et al. 2017. Oncotarget. 8: 40958-40966.
PMID: # 26312753 Mushtaq, M. et al. 2015. PLoS ONE. 10: e0136142.
PMID: # 23857601 Xu, M. et al. 2013. Clin. Cancer Res. 19: 4697-705.
PMID: # 23389829 Han, H. et al. 2013. Hepatology. 57: 2378-89.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.